Eptifibatide does not influence lymphocyte activation and CRP levels in patients with undergoing coronary angioplasty.
Inhibitors of the IIB-IIIA integrin are widely used to prevent stent thrombosis. Abciximab has been shown to attenuate the inflammatory response in patients undergoing PCI. Herein, we tested the effect of eptifibatide infused during PCI on peripheral lymphocyte activation and CRP levels before, and one month after the procedure showing no noticeable effect. These results may explain the differences in clinical outcome following PCI by use of different IIB-IIIA agents.
Finkelstein
Ariel
A
The Department of Cardiology, Tel Aviv Sourasky Medical Center, Israel.
Izraelov
Sabina
S
Roth
Arie
A
Ben-Shmuel
Sigal
S
Keren
Gad
G
Miller
Hylton
H
George
Jacob
J
D000368:Aged; D000369:Aged, 80 and over; D000789:Angina, Unstable / Q000097:blood* / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary; D002097:C-Reactive Protein / Q000187:drug effects* / Q000378:metabolism; D016516:CD4-CD8 Ratio; D000077542:Eptifibatide; D005260:Female; D005500:Follow-Up Studies; D006684:HLA-DR Antigens / Q000097:blood / Q000187:drug effects; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000494:pharmacology*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D015607:Stents; D013997:Time Factors
D006684:HLA-DR Antigens; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D002097:C-Reactive Protein; D000077542:Eptifibatide